Clinical question: in patients with atrial fibrillation, is rivaroxaban non-inferior to warfarin for the prevention of stroke or systemic embolism? Study design: multi-centre, randomized, double-blind, double-dummy, event-driven trial Inclusion criteria: Age ≥ 18 Non-valvular atrial fibrillation documented on ECG History of stroke, TIA or systemic embolism, or ≥ 2 of the following (i.e. CHADS2 ≥ 2) [...]
Clinical question: in patients with atrial fibrillation, is peri-operative heparin bridging required during interruption of warfarin therapy? Study design: randomized, double-blind placebo-controlled trial Inclusion criteria: Age ≥ 18 Permanent or paroxysmal atrial fibrillation / atrial flutter (confirmed by ECG / pacemaker interrogation), including valvular AF On warfarin for ≥ 3 months with a target INR of [...]
Clinical question: in patients with atrial fibrillation, is dabigatran non-inferior to warfarin for the prevention of stroke or systemic embolism? Study design: multinational randomized unblinded controlled trial comparing dabigatran with warfarin. Two doses of dabigatran (150mg BD and 110mg BD) also compared in a blinded fashion. Inclusion criteria: Documented atrial fibrillation on ECG Age > 18 [...]